A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 新出现的证据表明，炎症介质浸润肾脏的儿童先天性尿路病有助于肾功能的进行性下降，在这些患者中观察到。 使用免疫抑制治疗来预防进行性原发性非免疫性肾病的策略从未在涉及儿童或成人患者的临床实践中进行过测试。 本研究旨在验证以下假设：先天性尿路病患儿接受霉酚酸酯（MMF）给药安全、耐受性良好，并可预防先天性尿路病患者肾功能进行性下降。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Emerging evidence suggests that inflammatory mediators that infiltrate the kidney in children with congenital uropathies contribute to the progressive decline in kidney function that is observed in these patients. The strategy of using immunosuppressive therapy to protect against progressive, primary non-immunological forms of kidney disease has never been tested in clinical practice involving children or adult patients. This study is designed to test the hypothesis that administration of mycophenolate mofetil (MMF) to children with congenital uropathies will be safe and well tolorated and may prevent the progressive decline of kidney function in patients with congenital uropathies.